ClinicalTrials.gg
RecruitingNCT07052916Updated May 26, 2026

A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties

An interventional study of Music Therapy/MT and Therapist-Attention Music Education/TAME Control in Blood Cancer, Lymphoma and Leukemia, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Hematologic Neoplasms by Memorial Sloan Kettering Cancer Center — 4 open to participants now, 6 under way, none of them phase 3. Hematologic Neoplasms · Memorial Sloan Kettering Cancer Center.

Started
2025
with 1 other
No phase
2 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Hematologic Neoplasms by Memorial Sloan Kettering Cancer Center, this one is one of 2 that started in 2025, is one of 2 with no phase, and was the 10th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

4 of the 11 studies in Hematologic Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Hematologic Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function. Because of this past research, the researchers are doing this study to find out whether telehealth music therapy is a practical treatment for cognitive difficulties in blood cancer survivors. The researchers will also study whether music therapy and music education help improve cognitive function and other common symptoms such as anxiety, depression, and/or tiredness.

03

Conditions studied

  • Blood Cancer
  • Lymphoma
  • Leukemia
  • Myeloma

Keywords

  • Blood cancer survivor
  • myeloma
  • Leukemia
  • Lymphoma
  • Memorial Sloan Kettering Cancer Center
  • 25-119
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English-proficient, aged 18 or older
  • Diagnosis of lymphoma, leukemia, or myeloma
  • Stable oncologic disease or no evidence of disease as indicated in the medical chart or by the oncology team
  • Score of \<54 on the FACT-Cog PCI subscale
  • Minimum of one year as per clinician assessment
  • Patient should be able to understand and complete all study assessments on their own.
  • Eligible patient should be able to understand and provide signed informed consent in English.

Exclusion criteria

Exclusion Criteria:

  • Less than 3 months since completion of surgery, radiation, induction chemotherapy (for newly diagnosed or disease), transplantation, or immunotherapy (e.g., CAR T-Cell, bispecific antibodies)

    • If there is a defined treatment period, the patient must be at least 3 months from treatment completion
    • If the patient is on continuous therapy, patient must have completed at least 6 months of the therapy
    • Maintenance therapies are allowed
  • Received music therapy (MT) in the past year
  • Current music training, >6 months of music training in the past 10 years, or plan to initiate music training during the study
  • No access to an internet-connected device
  • Active suicidal ideation, bipolar, schizophrenia, or substance abuse
  • BOMC score ≥10 (indicative of dementia)
  • Uncorrectable visual, auditory, or motor impairments
  • Initiation or altered dose of sedative, stimulant, or anti-cholinergic medications in the past month or plan to initiate these medications during the study, as these are known to impact cognitive function
  • Initiation of any other interventions for CRCD (e.g., cognitive rehabilitation) in the past month or plan to initiate these interventions during the study, as these are known to impact cognitive function
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Music Therapy/MT

    Participants will receive 12, weekly 60-minute MT sessions (+/- 1 week) with homework in-between sessions to reinforce in-session concepts, practice musical skills, and serve as transitions to subsequent sessions

    Other: Music Therapy/MT

  • Active comparator
    Therapist Attention-Music Education/TAME control

    Patients will receive 12, weekly 60-minute Therapist Attention-Music Education/TAME sessions (+/- 1 week) with homework in-between sessions to reinforce in-session concepts and serve as transitions to subsequent sessions. The TAME control group will involve board-certified music therapists guiding participants through music listening exercises.

    Other: Therapist-Attention Music Education/TAME Control

  • No intervention
    Wait-List Control/WLC

    The Wait-List Control/WLC group will receive usual care from healthcare providers and complete the same assessments as the other groups. The WLC will have the option of receiving either 12 sessions of MT or 12 sessions of TAME intervention when the study concludes after the 24-week waiting period. The WLC participants will choose which intervention (MT or TAME) they wish to receive.

Interventions

  • OtherMusic Therapy/MT

    Therapeutic music lessons are the core component of the Music Therapy/MT intervention. Other components include guided music listening to help participants use music as a tool for regulating mood, energy, and attention, as well as music-centered discussions to help participants discover songs with personal meaning that they will enjoy learning to play.

  • OtherTherapist-Attention Music Education/TAME Control

    Participants will receive 12, weekly 60-minute TAME sessions (+/- 1 week) with homework in-between sessions to reinforce in-session concepts and serve as transitions to subsequent sessions. The TAME control group will involve board-certified music therapists guiding participants through music listening exercises.

06

What researchers measure

Primary outcomes

  1. Feasibility of studying a telehealth-based Music Therapy/MT intervention for cancer-related cognitive dysfunction/CRCD in hematologic cancer survivors as defined as the completion of 9 or more sessions.

    The primary objective of this study is to determine the feasibility of studying a telehealth-based Music Therapy/MT intervention for cancer-related cognitive dysfunction/CRCD in hematologic cancer survivors. Feasibility will be defined as the completion of 9 or more sessions out of the planned 12 weekly sessions of music therapy.

    Time frame: up to 1 year

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (All protocol activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Kevin Liou, MD · Contact646-608-8559
  • Memorial Sloan Kettering Monmouth (All protocol activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Kevin Liou, MD · Contact646-608-8559
  • Memorial Sloan Kettering Bergen (All protocol activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Kevin Liou, MD · Contact646-608-8559
  • Memorial Sloan Kettering Cancer Center Suffolk - Commack (All protocol activities)
    Commack, New York 11725, United States
    Recruiting
    • Kevin Liou, MD · Contact646-608-8559
  • Memorial Sloan Kettering Westchester (All protocol activities)
    Harrison, New York 10604, United States
    Recruiting
    • Kevin Liou, MD · Contact646-608-8559
  • Memorial Sloan Kettering Cancer Center (All protocol activities)
    New York, New York 10065, United States
    Recruiting
    • Kevin Liou, MD · Contact646-608-8563
  • Memorial Sloan Kettering Nassau (All protocol activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Kevin Liou, MD · Contact646-608-8559
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 18 months is below that.

Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 8, 2025
StartActual
Jun 27, 2025
Primary completionEst.
Dec 27, 2026
CompletionEst.
Dec 27, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07052916
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Jun 27, 2025
Primary completion
Dec 27, 2026 (estimated)
Completion
Dec 27, 2026 (estimated)
Last update
May 26, 2026

Study contacts

Kevin Liou, MD
Contact
liouk@mskcc.org
646-608-8563
Jun Mao, MD, MSCE
Contact
maoj@mskcc.org
646-608-8552
Kevin Liou, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion